Transcriptome Alterations in Prefrontal Pyramidal Cells Distinguish Schizophrenia From Bipolar and Major Depressive Disorders
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Background Impairments in certain cognitive processes (e.g., working memory) are typically most pronounced in schizophrenia (SZ), intermediate in bipolar disorder (BP) and least in major depressive disorder (MDD). Given that working memory depends, in part, on neural circuitry that includes pyramidal cells in layer 3 (L3) and layer 5 (L5) of the dorsolateral prefrontal cortex (DLPFC), we sought to determine if transcriptome alterations in these neurons were shared or distinctive for each diagnosis. Methods Pools of L3 and L5 pyramidal cells in the DLPFC were individually captured by laser-microdissection from 19 matched tetrads of unaffected comparison, SZ, BP and MDD subjects and the mRNA was subjected to transcriptome profiling by microarray. Results In DLPFC L3 and L5 pyramidal cells, transcriptome alterations were numerous in SZ subjects, but rare in BP and MDD subjects. The leading molecular pathways altered in SZ subjects involved mitochondrial energy production and the regulation of protein translation. In addition, we did not find any significant transcriptome signatures related to psychosis or suicide. Conclusions In concert, these findings suggest that molecular alterations in DLPFC L3 and L5 pyramidal cells might be characteristic of the disease process(es) operative in individuals diagnosed with SZ and thus might contribute to the circuitry alterations underlying cognitive dysfunction in individuals with this disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Direct Approach to False Discovery Rates
Storey, J. D. (2002) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00346 · Cited by 5,603
Cellular basis of working memory
Goldman-Rakic, P. S. (1995) · Neuron · doi:10.1016/0896-6273(95)90304-6 · Cited by 2,663
Schizophrenia risk from complex variation of complement component 4
Sekar, A., Bialas, A. R., de Rivera, H., Davis, A., Hammond, T. R., Kamitaki, N., Tooley, K., Presumey, J., Baum, M., Van Doren, V., et al. (2016) · Nature · doi:10.1038/nature16549 · Cited by 2,394
Decreased Dendritic Spine Density on Prefrontal Cortical Pyramidal Neurons in Schizophrenia
Glantz, L. A., & Lewis, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.1.65 · Cited by 1,636
Self-citationDe novo mutations in schizophrenia implicate synaptic networks
Fromer, M., Pocklington, A. J., Kavanagh, D. H., Williams, H. J., Dwyer, S., Gormley, P., Georgieva, L., Rees, E., Palta, P., Ruderfer, D. M., et al. (2014) · Nature · doi:10.1038/nature12929 · Cited by 1,617
A polygenic burden of rare disruptive mutations in schizophrenia
Purcell, S. M., Moran, J. L., Fromer, M., Ruderfer, D., Solovieff, N., Roussos, P., O’Dushlaine, C., Chambert, K., Bergen, S. E., Kähler, A., et al. (2014) · Nature · doi:10.1038/nature12975 · Cited by 1,385
Millan, M. J., Agid, Y., Brüne, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., Connor, R., Davis, S., Deakin, B., DeRubeis, R. J., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3628 · Cited by 1,292
Gene expression elucidates functional impact of polygenic risk for schizophrenia
Fromer, M., Roussos, P., Sieberts, S. K., Johnson, J. S., Kavanagh, D. H., Perumal, T. M., Ruderfer, D. M., Oh, E. C., Topol, A., Shah, H. R., et al. (2016) · Nature Neuroscience · doi:10.1038/nn.4399 · Cited by 1,091
Self-citationWorking memory dysfunction in schizophrenia
(1994) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.6.4.348 · Cited by 1,068
Schizophrenia Is a Cognitive Illness: Time for a Change in Focus
Kahn, R. S., & Keefe, R. S. E. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.155 · Cited by 825 · cited 1×
“This dysfunction is manifest as certain types of cognitive deficits, such as impairments in working memory (2).”
BackgroundDendritic spine pathology in schizophrenia
Glausier, J. R., & Lewis, D. A. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.04.044 · Cited by 581
Self-citationRajkowska, G., Selemon, L. D., & Goldman-Rakic, P. S. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.3.215 · Cited by 537 · cited 1×
“In the DLPFC of individuals with SZ, PCs in these layers exhibit morphological alterations such as smaller somal size, lower spine density and/or truncated dendritic trees (13-18).”
BackgroundAlterations in Cortical Network Oscillations and Parvalbumin Neurons in Schizophrenia
Gonzalez-Burgos, G., Cho, R. Y., & Lewis, D. A. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.03.010 · Cited by 497
Self-citationPlaisier, S. B., Taschereau, R., Wong, J. A., & Graeber, T. G. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq636 · Cited by 468
ROS and Brain Diseases: The Good, the Bad, and the Ugly
Popa-Wagner, A., Mitran, S., Sivanesan, S., Chang, E., & Buga, A.-M. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/963520 · Cited by 427
Bora, E., & Pantelis, C. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu198 · Cited by 341 · cited 1×
“The severity of these impairments typically differs across diagnoses, with impairments most pronounced in SZ, intermediate in BP and least in MDD (6, 7).”
BackgroundAltar, C. A., Jurata, L. W., Charles, V., Lemire, A., Liu, P., Bukhman, Y., Young, T. A., Bullard, J., Yokoe, H., Webster, M. J., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.03.031 · Cited by 318
The molecular bases of the suicidal brain
Turecki, G. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3839 · Cited by 281 · cited 1×
“Suicide has been reported to be associated with various gene expression alterations (40-43).”
BackgroundPierri, J. N., Volk, C. L. E., Auh, S., Sampson, A., & Lewis, D. A. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.5.466 · Cited by 257
Self-citationPathology of Layer V Pyramidal Neurons in the Prefrontal Cortex of Patients With Schizophrenia
Black, J. E., Kodish, I. M., Grossman, A. W., Klintsova, A. Y., Orlovskaya, D., Vostrikov, V., Uranova, N., & Greenough, W. T. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.4.742 · Cited by 250 · cited 1×
“In the DLPFC of individuals with SZ, PCs in these layers exhibit morphological alterations such as smaller somal size, lower spine density and/or truncated dendritic trees (13-18).”
BackgroundKolluri, N., Sun, Z., Sampson, A. R., & Lewis, D. A. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.6.1200 · Cited by 241 · cited 3×
“This interpretation is consistent with previous reports that alterations in soma size (17) and dendritic spine density (18) in SZ are more pronounced in L3 than L5 PCs.”
BackgroundResultSelf-citationCross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression
Huang, J., Perlis, R. H., Lee, P. H., Rush, A. J., Fava, M., Sachs, G. S., Lieberman, J., Hamilton, S. P., Sullivan, P., Sklar, P., et al. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09091335 · Cited by 213
Arion, D., Corradi, J. P., Tang, S., Datta, D., Boothe, F., He, A., Cacace, A. M., Zaczek, R., Albright, C. F., Tseng, G., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.171 · Cited by 177 · cited 10×
“The percentage of genes altered in both pathways, and the statistical significance of the pathway finding, was larger in L3 than in L5 PCs, consistent with our previous study showing a greater oxphos-mitochondrial signature in L3 than L5 PCs in SZ (21).”
BackgroundMethodResultInfluentialSelf-citationCognitive impairment in bipolar disorder and schizophrenia: a systematic review
Vöhringer, P. A., Barroilhet, S. A., Amerio, A., Reale, M. L., Alvear, K., Vergne, D., & Ghaemi, S. N. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00087 · Cited by 165 · cited 2×
“Furthermore, at least some psychotic features are thought to emerge from cognitive disturbances that are shared, albeit to different degrees, across all three diagnoses (3-5, 37).”
BackgroundCognitive impairments in psychotic disorders: common mechanisms and measurement
Barch, D. M., & Sheffield, J. M. (2014) · World Psychiatry · doi:10.1002/wps.20145 · Cited by 154
The Neurobiology of Thought: The Groundbreaking Discoveries of Patricia Goldman-Rakic 1937-2003
Arnsten, A. F. T. (2013) · Cerebral Cortex · doi:10.1093/cercor/bht195 · Cited by 94
Analyzing Schizophrenia by DNA Microarrays
Horváth, S., Janka, Z., & Mirnics, K. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.07.017 · Cited by 64 · cited 1×
“Microarray studies have traditionally been validated by assessing a small set of transcripts using qPCR, with recent studies typically demonstrating very high validation rates (28).”
Background
Cited by
The origin of NMDA receptor hypofunction in schizophrenia
Nakazawa, K., & Sapkota, K. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107426 · Cited by 275
Alterations in cortical interneurons and cognitive function in schizophrenia
Dienel, S. J., & Lewis, D. A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.06.020 · Cited by 272
Self-citationSmucny, J., Dienel, S. J., Lewis, D. A., & Carter, C. S. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-021-01089-0 · Cited by 231
Self-citationTranscriptome alterations of prefrontal cortical parvalbumin neurons in schizophrenia
Enwright III, J. F., Huo, Z., Arion, D., Corradi, J. P., Tseng, G., & Lewis, D. A. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.216 · Cited by 109
Self-citationDong, Z., Yan, Q., & Wang, X. (2022) · Disease Markers · doi:10.1155/2022/2148627 · Cited by 1
Metadata
- Authors
- Arion, D., Huo, Z., Enwright, J. F., Corradi, J. P., Tseng, G., & Lewis, D. A.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2017-10
- Volume
- 82
- Issue
- 8
- Pages
- 594-600
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W2604293392
- Cited by
- 122
- References
- 27
- FWCI
- 10.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.